Azcuris partners with AstraZeneca for new drug discovery
Translated from Korean, summarized and contextualized by DistantNews.
At a glance
News
Sources not specified
New plan
- South Korean biotech venture Azcuris has signed a joint research agreement with AstraZeneca.
- The collaboration focuses on discovering small molecule drugs for respiratory and Th2-mediated diseases like asthma and atopic dermatitis.
- This partnership highlights a South Korean biotech's advancement through its proprietary technology with a global pharmaceutical giant.
South Korean biotech startup Azcuris is embarking on a significant collaboration with British pharmaceutical giant AstraZeneca. The two companies have entered into a joint research agreement aimed at discovering novel small molecule drugs for treating respiratory and Th2-mediated diseases.
Th2-mediated conditions include common ailments such as asthma, atopic dermatitis, and allergic rhinitis. This partnership leverages Azcuris's proprietary technology, marking a notable step for a domestic biotech firm engaging with a global pharmaceutical leader.
The agreement signifies a growing trend of international pharmaceutical companies seeking innovative solutions from smaller, specialized biotech firms. Azcuris's success in securing this deal underscores the potential of its technological platform in developing new therapeutic options for challenging diseases.
DistantNews Editorial
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.
More Stories
From Our Blog
What Gets Lost (and Found) When News Is Translated
The Critical Role of Diaspora Media in Global News
What Travellers Should Know About Countries with Restricted Press
A Digital Nomad's Guide to Following Local News
How the Same Story Looks Different in Different Countries
